<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20051227/bs_nm/bostonscientific_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051227/2005_12_27t083935_360x450_us_guidant.jpg?x=103&amp ;y=130&amp;sig=u0p3aHg3LfrroZtB8dGmuA--" align="left" height="130" width="103" alt="A view of Guidant's Prizm 2 DR defibrillator in an undated publicity photo. Guidant projected that some patients might die as result of short circuits in the device, the New York Times reported. Guidant said on Tuesday that it has received a warning letter from the U.S. Food and Drug Administration related to the agency's prior inspection of the company's heart rhythm management device facility in St. Paul, Minnesota. (Handout/Reuters)" border="0" /></a>Reuters - Boston Scientific Corp. said on
Tuesday it will continue with its plans to acquire rival
medical device maker Guidant Corp. despite Guidant's
issuance last week of a profit warning.</p><br clear=all>

View the entire article: Boston Scientific says will stay with Guidant deal (Reuters)